文献速递眼底病与葡萄膜炎

针对糖尿病黄斑水肿伴周边视网膜无灌注的靶向视网膜光凝:三年随机DAVE试验

Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
PubMed 文献 · Ophthalmology · 2018-01-11

这项I/II期前瞻性随机对照试验将40只眼(29例患者)的中心受累糖尿病黄斑水肿眼随机分为雷珠单抗单药组与雷珠单抗联合靶向视网膜光凝组,随访36个月。结果显示联合治疗未改善视力预后或减少治疗负担,两组最佳矫正视力平均改善分别为13.9和8.2个字母(P=0.20),中央视网膜厚度改善分别为302和152微米(P=0.03),注射次数分别为24.4和27.1次。

要点

  • 联合靶向视网膜光凝未改善糖尿病黄斑水肿患者的视力预后(P=0.20)
  • 联合治疗组中央视网膜厚度改善更明显(302 vs 152微米,P=0.03)
  • 联合治疗组注射次数更多(24.4 vs 27.1次,P=0.004),未减少治疗负担

核心结论

  • 在这项纳入40只糖尿病黄斑水肿眼的3年随机试验中,无证据表明雷珠单抗联合靶向视网膜光凝较单用雷珠单抗改善视力预后或减少治疗负担。

研究设计与样本

  • I/II期前瞻性随机对照临床试验,纳入29例患者的40只中心受累糖尿病黄斑水肿眼,按1:1随机分为雷珠单抗单药组或雷珠单抗联合靶向视网膜光凝组,随访36个月。

主要发现

  • 第36个月时,单药组与联合治疗组的最佳矫正视力平均分别改善13.9和8.2个字母(P=0.20),中央视网膜厚度平均分别改善302和152微米(P=0.03)。
  • 至第36个月,单药组与联合治疗组平均注射次数分别为24.4次(范围10-34)和27.1次(范围12-36),按需注射执行比例分别为73%(362/496)和80%(433/538)(P=0.004)。
  • Goldmann视野III-4e等视线面积在单药组与联合治疗组分别减少2%和18%(P=0.30)。

关键数值与推荐

  • 纳入标准为中心受累糖尿病黄斑水肿且ETDRS最佳矫正视力在20/32至20/320(Snellen等效)之间。
  • 所有眼接受4次每月雷珠单抗0.3 mg注射,随后每月检查并按需再治疗至36个月。
  • 联合治疗组在周1对黄斑外视网膜毛细血管无灌注区加1个视盘面积边缘行靶向视网膜光凝,并在第6、18、25个月根据需要再治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of targeted retinal photocoagulation (TRP) on visual and anatomic outcomes and treatment burden in eyes with diabetic macular edema (DME). DESIGN: Phase I/II prospective, randomized, controlled clinical trial. PARTICIPANTS: Forty eyes of 29 patients with center-involved macular edema secondary to diabetes mellitus. METHODS: Eyes with center-involved DME and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) between 20/32 and 20/320 (Snellen equivalent) were randomized 1:1 to monotherapy with 0.3 mg ranibizumab (Lucentis, Genentech, South San Francisco, CA) or combination therapy with 0.3 mg ranibizumab and TRP guided by widefield fluorescein angiography. All eyes received 4 monthly ranibizumab injections followed by monthly examinations and pro re nata (PRN) re-treatment through 36 months. Targeted retinal photocoagulation was administered outside the macula to areas of retinal capillary nonperfusion plus a 1-disc area margin in the combination therapy arm at week 1, with re-treatment at months 6, 18, and 25, if indicated. MAIN OUTCOME MEASURES: Mean change in ETDRS BCVA from baseline and number of intravitreal injections administered. RESULTS: At baseline, mean age was 55 years, mean BCVA was 20/63 (Snellen equivalent), and mean central retinal subfield thickness (CRT) was 530 μm. Thirty-four eyes (85%) completed month 36, at which point mean BCVA improved 13.9 and 8.2 letters (P = 0.20) and mean CRT improved 302 and 152 μm (P = 0.03) in the monotherapy and combination therapy arms, respectively. The mean number of injections administered through month 36 was 24.4 (range, 10-34) and 27.1 (range, 12-36), with 73% (362/496) and 80% (433/538) of PRN injections administered (P = 0.004) in the monotherapy and combination therapy arms, respectively. Goldmann visual field isopter III-4e area decreased by 2% and 18% in the monotherapy and combination therapy arms, respectively (P = 0.30). CONCLUSIONS: In this 3-year randomized trial of 40 eyes with DME, there was no evidence that combination therapy with ranibizumab and TRP improved visual outcomes or reduced treatment burden compared with ranibizumab alone.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Brown DM, Ou WC, Wong TP, et al. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018. PMID: 29336896. doi:10.1016/j.ophtha.2017.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。